RYWECK DANIEL E. (Chief Financial Officer) purchased 25.0% of their position (1K shares) of SILO PHARMA, INC. on the open market
Open‑market purchase worth $2.1K — a significant purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 5/26/2023ACC: 0001213900-23-043531
Officer· Chief Financial Officer
Since Sep 2022
+1K
Net shares
Net buyer
$2.1K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
1K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+1K
Price / share
$2.13
Trade value
$2.13K
% of position
25.0%
5/26/2023
4K→5K
Total
Net shares
+1K
Net value
$2.13K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/26/2023 | P · Purchase | +1K | $2.13 | $2.13K | 25.0% | 4K | 5K |
| Total | +1K | $2.13K | ||||||
Derivative Transactions0
No derivative transactions reported